A recombinant modified vaccinia virus Ankara expressing prME of tick-borne encephalitis virus affords mice full protection against TBEV infection
Introduction
Tick-borne encephalitis virus (TBEV) is an important human pathogen that can cause a serious disease involving the central nervous system (tick-borne encephalitis, TBE). Although approved inactivated vaccines are available, the number of TBE cases is rising, and breakthrough infections in fully vaccinated subjects have been reported in recent years.
Methods
In the present study, we generated and characterized a recombinant Modified Vaccinia virus Ankara (MVA) for the delivery of the pre-membrane (prM) and envelope (E) proteins of TBEV (MVA-prME).
Results
MVA-prME was tested in mice in comparison with a licensed vaccine FSME-IMMUN® and proved to be highly immunogenic and afforded full protection against challenge infection with TBEV.
Discussion
Our data indicate that MVA-prME holds promise as an improved next-generation vaccine for the prevention of TBE.
Preview
Cite
Access Statistic
Rights
Use and reproduction:
